-5%
Reversair is prescribed for:
Long-term management and prevention of asthma.
Acute prevention of Exercise-Induced Bronchoconstriction (EIB).
Relief of symptoms of allergic rhinitis (both seasonal & perennial).
Class: Selective Leukotriene Receptor Antagonist
Montelukast specifically blocks CysLT1 receptors, preventing the action of leukotrienes (LTC4, LTD4, LTE4).
This inhibition reduces airway edema, smooth muscle contraction, and inflammatory cell activation.
Clinical benefit: improves asthma control and relieves allergic rhinitis symptoms.